All In Biotech

Drug Trial Radar · NCT06005974

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation

Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

18

Actual

Start

Jan 15, 2024

Primary completion

Feb 24, 2025

Study completion Feb 24, 2025

Sponsor

Lead sponsor
Recursion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.

Conditions

  • AXIN1 Gene Mutation
  • APC Gene Mutation
  • Solid Tumor

Interventions

  • REC-4881Drug

    REC-4881 4mg capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting ToxicitiesTime frame: Up to 24 months
  2. Objective Response RateTime frame: Up to 24 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Sharp Memorial Hospital

    San Diego, California

  • Sansum Clinic

    Santa Barbara, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Eastern Connecticut Hematology & Oncology Associates

    Norwich, Connecticut

  • Medical Oncology Hematology Consultants

    Newark, Delaware

  • Cancer Specialists of North Florida

    Fleming Island, Florida

  • Mission Cancer And Blood

    Des Moines, Iowa

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Saint Luke's Hospital

    Kansas City, Missouri

  • Hunterdon Hematology Oncology

    Hillsborough, New Jersey

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Mary Crowley Cancer Research Centers

    Dallas, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.